Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).
News | Stroke
Preventing Millions of Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding

December 14, 2022 — Verseon announced that the European Journal of Medicinal Chemistry has published a paper describing ...

Home December 14, 2022
Home
Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry
News | Atrial Fibrillation
Field Medical and CardioNXT Collaborate to Deliver Novel Integration of Focal Pulsed Field Ablation And 3D Mapping & Navigation For Treatment of Cardiac Arrhythmias

December 14, 2022 — Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of ...

Home December 14, 2022
Home
Corindus, A Siemens Healthineers Company, has officially rebranded as Siemens Healthineers
News | Cardiovascular Business
Corindus, A Siemens Healthineers Company, Is Now Siemens Healthineers Endovascular Robotics

December 14, 2022 — Corindus, A Siemens Healthineers Company, has been rebranded to Siemens Healthineers Endovascular ...

Home December 14, 2022
Home
Series to feature leading experts discussing the current and future trends in the carotid treatment market
News | Stents Carotid
InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home December 13, 2022
Home
Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.
News | Structural Heart
Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single ...

Home December 13, 2022
Home
Image courtesy of Intermountain Healthcare
News | Cardiovascular Clinical Studies
Study Finds Patients Without Standard Modifiable Heart Risk Factors Are Common and More Likely to Fare Better After Heart Attack Than Patients with Known Factors

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without ...

Home December 13, 2022
Home
The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between 2022 and 2025, driven by increasing population at a risk of cardiovascular diseases.
News | Pacemakers
Global Pacemakers Market Set to Grow at 5.4% CAGR Over Next 3 Years

December 12, 2022 — The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between ...

Home December 12, 2022
Home
Michael A. Mussallem
News | Cardiovascular Business
Edwards Lifesciences Announces CEO Succession Plan

December 12, 2022 — Edwards Lifesciences Corporation announced that following regular succession planning discussions ...

Home December 12, 2022
Home
US-based Weill Cornell Medicine has initiated a new clinical project together with the Mwanza International Trials Unit located in the Lake Zone of Tanzania with the aim of exploring the burden of arrhythmia in adults with and without HIV.
News | Artificial Intelligence
Weill Cornell Medicine partners with Poland-based company Cardiomatics to investigate the relationship between HIV and heart rhythm disorders

December 12, 2022 — US-based Weill Cornell Medicine has initiated a new clinical project together with the Mwanza ...

Home December 12, 2022
Home
Clinical abstract focuses on value of PURE EP’s and its groundbreaking High Frequency Algorithm (HFA) during pulmonary vein isolation
News | Cardiovascular Clinical Studies
BioSig’s PURE EP System Highlighted in the Journal of Atrial Fibrillation and Electrophysiology

December 9, 2022 — BioSig Technologies, Inc. an advanced digital signal processing technology company delivering ...

Home December 09, 2022
Home
Dr. Rami Kahwash, director of Ohio State’s Heart and Vascular Research Organization and a professor of clinical medicine in the Ohio State College of Medicine.
News | Cardiovascular Clinical Studies
Ohio State First in World to Participate in Trial Confirming Efficacy of Novel Heart Failure Treatment

December 9, 2022 — The Ohio State University Wexner Medical Center is first in the world to randomize a patient in a ...

Home December 09, 2022
Home
News | Cardiovascular Clinical Studies
Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

December 9, 2022 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies ...

Home December 09, 2022
Home
Cardiac care should follow the patient on a virtual journey and deliver high-fidelity insights to care providers, eliminating the gaps in data transmission
News | Remote Monitoring
With Minutes Between Life and Death, Continuous Remote ECG Monitoring Saves Lives

December 8, 2022 — Heart disease is the number one killer in the U.S., and high-fidelity monitoring is the beginning of ...

Home December 08, 2022
Home
Along with physician leaders and members, the society has helped the subspecialty officially join NRMP’s Medical Specialties Matching Program in 2025
News | SCAI
SCAI Leads the Way for Interventional Cardiology to Join “The Match”

December 8, 2022 — The Society for Cardiovascular Angiography & Interventions (SCAI), a leading nonprofit medical ...

Home December 08, 2022
Home
Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint
News | Cardiovascular Clinical Studies
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL (bempedoic acid) Meets Primary Endpoint

December 8, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting ...

Home December 08, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now